Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)

Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Patients & methods: Outpatient adults/adolescents with mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Horga, Arantxa, Saenz, Rebecca, Yilmaz, Gürdal, Simón-Campos, Abraham, Pietropaolo, Keith, Stubbings, William J, Collinson, Neil, Ishak, Laura, Zrinscak, Barbara, Belanger, Bruce, Granier, Catherine, Lin, Kai, C Hurt, Aeron, Zhou, Xiao-Jian, Wildum, Steffen, Hammond, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621114/
https://www.ncbi.nlm.nih.gov/pubmed/37928891
http://dx.doi.org/10.2217/fvl-2023-0115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621114/
https://www.ncbi.nlm.nih.gov/pubmed/37928891
http://dx.doi.org/10.2217/fvl-2023-0115

Ejemplares similares